Xarelto for Real Life Anticoagulation in Pulmonary Embolism (PE) in China

Xarelto® for Real Life Anticoagulation in Pulmonary Embolism (PE) in China

EINSTEIN PE study demonstrated that rivaroxaban is at least as effective as the current standard therapy with 51% relative risk reduction of major bleeding (1.1% vs. 2.2%, HR 0.49, 95% CI, 0.31-0.79), in the treatment and secondary prevention of PE. However these patients were required to meet strict eligibility criteria. Little is known about PE treatment in China in routine clinical practice and in a real world study patients at higher or lower risk for adverse events can possibly recruited. Bayer conducts this study to yield post-authorization safety information in rivaroxaban under real-life conditions in China.

Xarelto for Real Life Anticoagulation in Pulmonary Embolism (PE) in China

Recruitment

Summary

Participation Requirements

Description

Tracking Information